About Adamas
Overview
Management Team
Board of Directors
Scientific & Clinical Advisors
Investors
Contact Us
Product Pipeline
Pipeline Overview
ADS-5102
MDX-8704
ADS-8704
ADS-8902
Clinical Trials
Partners
Newsroom
Press Releases
Presentations & Publications
Careers
Job Postings
Benefits
Press Releases
Press Releases
Presentations & Publications
Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease — June 18, 2013
Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinson's Disease — June 10, 2013
Adamas Pharmaceuticals Announces Issuance of First US Patent for ADS-5102 (Amantadine HCL Extended Release) Program — April 22, 2013
Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data from its ADS-5102 (Nurelin™) Program at American Academy of Neurology Conference — March 20, 2013
Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer’s Disease — November 13, 2012
Click
here
for the Press Release Archive.
Back to top »
© 2013 Adamas Pharmaceuticals, Inc.